What is the appropriate treatment for a patient with an estimated glomerular filtration rate of 35 mL/min/1.73 m²?

Treatment for GFR 35 mL/min/1.73 m²

For a patient with eGFR 35 mL/min/1.73 m² (CKD Stage 3b), you should initiate SGLT2 inhibitor therapy and optimize RAS inhibition (ACEi or ARB) based on albuminuria status, while implementing comprehensive CKD management including blood pressure control and monitoring for complications.

Core Pharmacologic Interventions

SGLT2 Inhibitors - First Priority

• Start an SGLT2 inhibitor immediately for patients with eGFR ≥20 mL/min/1.73 m² 1, 2
• This applies regardless of diabetes status if:
  • Urine ACR ≥200 mg/g (≥20 mg/mmol), OR
  • Heart failure is present (any albuminuria level) 1
• For eGFR 20-45 mL/min/1.73 m² with ACR <200 mg/g: SGLT2i is still recommended but with slightly lower strength of evidence 1
• Continue SGLT2i even if eGFR drops below 20 mL/min/1.73 m² once initiated, unless intolerance or dialysis begins 1

Key monitoring point: The initial eGFR decline <30% after SGLT2i initiation reflects beneficial hemodynamic changes (reduced glomerular hyperfiltration) and should NOT prompt discontinuation 3. This decline is reversible and predicts greater long-term kidney protection.

RAS Inhibition - Second Priority

The approach depends on albuminuria and diabetes status:

With diabetes:

• Start ACEi or ARB for moderately-to-severely increased albuminuria (A2 or A3) 1
• Use the highest approved tolerated dose 1

Without diabetes:

• Start ACEi or ARB for severely increased albuminuria (A3) - strong recommendation 1
• Consider starting for moderately increased albuminuria (A2) - weaker recommendation 1

Critical continuation rule: Continue ACEi/ARB even when eGFR falls below 30 mL/min/1.73 m² 1. Only reduce or stop if:

• Serum creatinine rises >30% within 4 weeks of initiation/dose increase
• Symptomatic hypotension occurs
• Uncontrolled hyperkalemia despite medical management
• eGFR <15 mL/min/1.73 m² with uremic symptoms 1

Blood Pressure Management

• Target office SBP <130 mmHg (ideally 120-129 mmHg for most patients)
• Check BP, creatinine, and potassium 2-4 weeks after starting or increasing RASi dose 1
• Manage hyperkalemia with potassium-lowering measures rather than stopping RASi 1

Monitoring and Complication Management

At eGFR 35, you must actively screen for and treat CKD complications:

Essential monitoring:

• Anemia screening and treatment
• Bone mineral metabolism abnormalities (calcium, phosphate, PTH, vitamin D)
• Hyperkalemia surveillance
• Metabolic acidosis assessment
• Volume status evaluation
• Cardiovascular risk factor optimization 4

Monitoring frequency: The initial eGFR decline with SGLT2i or RASi does not require increased monitoring frequency beyond standard CKD protocols 1

Common Pitfalls to Avoid

1. Do not discontinue SGLT2i for initial eGFR dip: An acute decline <30% is hemodynamically beneficial, not harmful 3

2. Do not stop RASi prematurely: Hyperkalemia can often be managed medically without stopping the drug 1

3. Do not withhold SGLT2i during routine care: Only withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1

4. Do not delay nephrologist referral: At GFR 35, nephrology co-management should be established if not already in place 4

Preparation for Advanced CKD

While not imminent at GFR 35, begin discussing:

• Kidney replacement therapy options (dialysis vs. transplantation)
• Vascular access planning if progression continues
• Transplant evaluation eligibility 4

The combination of SGLT2i and RASi provides additive kidney protection through complementary mechanisms - SGLT2i reduces glomerular hyperfiltration while RASi blocks maladaptive renin-angiotensin activation 1, 3.